A Phase 1 Study of VT3989 in People With Mesothelioma


Full Title

Phase 1, Multi-Center, Open-Label Study of VT3989 in Patients with Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the Neurofibromatosis Type 2 Gene (mutant NF2 or mNF2)


Researchers are assessing the safety of the drug VT3989 in people with mesothelioma. The people in this study have mesothelioma with a mutation (change or variant) in the NF2 gene.

VT3989 blocks proteins in the body that can cause tumors to grow. By blocking these proteins, VT3989 may help slow or stop the growth of cancer cells. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have mesothelioma that contains an NF2 mutation.
  • Have finished prior therapies at least 2 weeks before taking VT3989.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Marjorie Zauderer’s office at 646-608-3790.




Phase I (phase 1)

Disease Status

Relapsed or Refractory




ClinicalTrials.gov ID